These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16718947)

  • 61. Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
    Sánchez-Ballester F; Miranda P; Lizarraga I; Rejas J; Arumi D
    Actas Urol Esp; 2014 Apr; 38(3):156-63. PubMed ID: 24119382
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Olshansky B; Serra DB
    Clin Pharmacol Ther; 2008 Feb; 83(2):231-2; author reply 233. PubMed ID: 18043690
    [No Abstract]   [Full Text] [Related]  

  • 63. Visual hallucinations at the onset of tolterodine treatment in a patient with a high-level spinal cord injury.
    Malavaud B; Bagheri H; Senard JM; Sarramon JP
    BJU Int; 1999 Dec; 84(9):1109. PubMed ID: 10571650
    [No Abstract]   [Full Text] [Related]  

  • 64. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
    Diokno AC; Appell RA; Sand PK; Dmochowski RR; Gburek BM; Klimberg IW; Kell SH;
    Mayo Clin Proc; 2003 Jun; 78(6):687-95. PubMed ID: 12934777
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
    Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
    Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Fesoterodine for the treatment of overactive bladder.
    Tzefos M; Dolder C; Olin JL
    Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns.
    Novara G; Cornu JN
    Eur Urol; 2013 Feb; 63(2):306-8. PubMed ID: 23201469
    [No Abstract]   [Full Text] [Related]  

  • 68. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine.
    Kobelt G; Kirchberger I; Malone-Lee J
    BJU Int; 1999 Apr; 83(6):583-90. PubMed ID: 10233562
    [No Abstract]   [Full Text] [Related]  

  • 70. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
    Goepel M
    Urologe A; 2006 Jul; 45(7):847-51. PubMed ID: 16816976
    [No Abstract]   [Full Text] [Related]  

  • 71. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams.
    Chung DE; Te AE; Staskin DR; Kaplan SA
    Urology; 2010 May; 75(5):1144-8. PubMed ID: 20206978
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial.
    Homma Y; Kawabe K
    World J Urol; 2004 Oct; 22(4):251-6. PubMed ID: 15455256
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
    Malone-Lee J; Shaffu B; Anand C; Powell C
    J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Safety of solifenacin and tolterodine in the treatment of overactive bladder: a meta-analysis].
    Xu C; Jiang XZ; Zhang NZ; Zhao HF; Xu ZS
    Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(48):3398-402. PubMed ID: 23327698
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin.
    Nordstrom BL; Evans MA; Murphy BR; Nutescu EA; Schein JR; Bookhart BK
    Curr Med Res Opin; 2015 Mar; 31(3):439-47. PubMed ID: 25495136
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity--a comment.
    Short DD
    Pharmacotherapy; 1999 Oct; 19(10):1188. PubMed ID: 10512072
    [No Abstract]   [Full Text] [Related]  

  • 77. Risk of serious falls associated with oxybutynin and tolterodine: a population based study.
    Gomes T; Juurlink DN; Ho JM; Schneeweiss S; Mamdani MM
    J Urol; 2011 Oct; 186(4):1340-4. PubMed ID: 21855905
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment of the overactive bladder with tolterodine, a new muscarinic receptor antagonist.
    Messelink EJ
    BJU Int; 1999 Mar; 83 Suppl 2():48-52. PubMed ID: 10210605
    [No Abstract]   [Full Text] [Related]  

  • 79. A re-appraisal of warfarin control in the treatment of deep vein thrombosis and / or pulmonary embolism.
    Amiwero C; Campbell IA; Prescott RJ
    Afr Health Sci; 2009 Sep; 9(3):179-85. PubMed ID: 20589148
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Tolterodine for treatment of overactive bladder.
    Kanofsky JA; Nitti VW
    Urol Clin North Am; 2006 Nov; 33(4):447-53, viii. PubMed ID: 17011380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.